Category Archives: News
The tight junction protein ZO-1 is dispensable for barrier function but critical for effective mucosal repair
S AND AIMS: Increased permeability is implicated in the pathogenesis of intestinal disease. In vitro and in vivo studies have linked downregulation of the scaffolding protein ZO-1, encoded by the TJP1 gene, to increased tight junction permeability. Thi… Continue reading
Posted in News
Comments Off on The tight junction protein ZO-1 is dispensable for barrier function but critical for effective mucosal repair
LTE Reply to 21-00786 and 21-01414
Posted in News
Comments Off on LTE Reply to 21-00786 and 21-01414
Covering the Cover
The optimal age to stop endoscopic surveillance for nondysplastic Barrett’s esophagus depends on sex and comorbidity level. Continue reading
Posted in News
Comments Off on Covering the Cover
713d Downregulation of Apolipoprotein H Induce Hepatocyte Steatosis to Promote Gut Microbiota Dysbiosis in Chronic Hepatitis B Infection
Apolipoprotein H (apoH) is produced by hepatocytes and also an acute phase protein in hepatitis B virus (HBV) infection. We found HBV and the large surface antigen upregulate apoH expression, which inhibits HBsAg secretion and then induces ER stress. A… Continue reading
Posted in News
Comments Off on 713d Downregulation of Apolipoprotein H Induce Hepatocyte Steatosis to Promote Gut Microbiota Dysbiosis in Chronic Hepatitis B Infection
775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study
Head-to-head trials are important to inform patient (pt) and physician choice. We studied the efficacy and safety of ustekinumab (UST) vs adalimumab (ADA) through 1 year in biologic-naïve pts with moderate-to-severe Crohn’s disease (CD). Continue reading
Posted in News
Comments Off on 775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study
775e Active Herpes Simplex Virus Type 1 Infection of the Gastric Mucosa is Associated with Functional Gastrointestinal Disorders: A Pilot Case-Control Study
Neurotropic herpes viruses establish lifelong latent infections in ganglionic neurons, including intrinsic enteric neurons and extrinsic neurons that project to the GI tract. Upon reactivation, virus replication within innervated tissues can result in … Continue reading
Posted in News
Comments Off on 775e Active Herpes Simplex Virus Type 1 Infection of the Gastric Mucosa is Associated with Functional Gastrointestinal Disorders: A Pilot Case-Control Study
713c Dietary Fat Increases Intestinal Fructose Conversion to Glycerate that Accumlates in Circulation, Driving Glucose Intolerance
The development of type II diabetes mellitus (T2DM) is strongly associated with consuming a western diet, high in sugars and fats. Metabolites from both dietary fats and carbohydrates can regulate each other through transcriptional regulators like carb… Continue reading
Posted in News
Comments Off on 713c Dietary Fat Increases Intestinal Fructose Conversion to Glycerate that Accumlates in Circulation, Driving Glucose Intolerance
775f The Introduction of Faecal Immunochemical Testing as a Triaging Tool for Colorectal Cancer Investigation During the COVID-19 Pandemic. A Service Evaluation and Report.
The covid-19 pandemic has caused unprecedented difficulties within GI endoscopy. In the UK, this has included a five-week suspension of all non-emergency endoscopy from March 2020, followed by a prolonged recovery period. Endoscopy activity remains at … Continue reading
Posted in News
Comments Off on 775f The Introduction of Faecal Immunochemical Testing as a Triaging Tool for Colorectal Cancer Investigation During the COVID-19 Pandemic. A Service Evaluation and Report.
775b Olamkicept, an IL-6 Trans-Signaling Inhibitor, is Effective for Induction of Response and Remission in A Randomized, Placebo-Controlled Trial in Moderate to Severe Ulcerative Colitis
IL-6 trans-signaling blockade inhibits chronic inflammation in human lamina propria1. Trans-signaling inhibition may have safety advantages over pan-IL-6 inhibitors (i.e. IL-6 or IL-6R antibodies) by preserving membrane IL-6R signaling. We evaluated th… Continue reading
Posted in News
Comments Off on 775b Olamkicept, an IL-6 Trans-Signaling Inhibitor, is Effective for Induction of Response and Remission in A Randomized, Placebo-Controlled Trial in Moderate to Severe Ulcerative Colitis
775c A Phase 2 Randomized Controlled Trial Demonstrating the Efficacy and Safety of Shr0302, A Selective JAK1 Inhibitor for the Treatment of Moderate to Severe Ulcerative Colitis Patients.
SHR0302 is a selective JAK1 inhibitor. A global, randomized, placebo-controlled phase 2 study (AMBER2; NCT03675477) consisting of an 8-week induction + 8-week extension period, was conducted to evaluate the efficacy and safety of SHR0302 in moderate to… Continue reading
Posted in News
Comments Off on 775c A Phase 2 Randomized Controlled Trial Demonstrating the Efficacy and Safety of Shr0302, A Selective JAK1 Inhibitor for the Treatment of Moderate to Severe Ulcerative Colitis Patients.